Popular terms

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Vaccine patents



      

This page is updated frequently with new Vaccine-related patent applications.




Date/App# patent app List of recent Vaccine-related patents
07/21/16
20160208223 
 High titer recombinant influenza viruses for vaccines patent thumbnailnew patent High titer recombinant influenza viruses for vaccines
The invention provides a composition useful to prepare high titer influenza viruses, e.g., in the absence of helper virus, which includes at least five internal genes from an influenza virus isolate that replicates to high titers in embryonated chicken eggs or mdck cells.. .
Wisconsin Alumni Research Foundation (warf)


07/21/16
20160207964 
 Designing a soluble full-length hiv-1 gp41 trimer patent thumbnailnew patent Designing a soluble full-length hiv-1 gp41 trimer
Described herein is a soluble hiv-1 retrovirus transmembrane glycoprotein gp41 trimer (soc-gp41m-fd) containing a partial ectodomain and the cytoplasmic domain, that is fused to the small outer capsid (soc) protein of bacteriophage t4 and the foldon domain of the bacteriophage t4 fibritin (fd). The gp41 trimer that has a prehairpin structure could be utilized to understand the mechanism of viral entry and as a candidate for development of hiv-1 vaccines, diagnostics and therapeutics.
The Catholic University Of America


07/21/16
20160206728 
 Dried influenza vaccine preparation and  producing the same patent thumbnailnew patent Dried influenza vaccine preparation and producing the same
The present invention provides a dried influenza vaccine preparation in which the activity of an influenza vaccine antigen can be stably maintained even when stored without strictly maintaining a low temperature, and which can be stably supplied. The present invention also provides a method of producing the dried influenza vaccine preparation.
Nitto Denko Corporation


07/21/16
20160206724 
 Methods and compositions related to reorganization of arenavirus genome for development of novel arenavirus live-attenuated vaccines (lav) patent thumbnailnew patent Methods and compositions related to reorganization of arenavirus genome for development of novel arenavirus live-attenuated vaccines (lav)
Disclosed are compositions and methods related to recombinant arenaviruses and their use in vaccines for the treatment or prevention of an arenavirus infection.. .
University Of Rochester


07/21/16
20160206721 
 Bacterial vaccine and methods for manufacture thereof patent thumbnailnew patent Bacterial vaccine and methods for manufacture thereof
Disclosed are stable conjugate vaccine formulations for protection against salmonella typhi, and methods of conjugation between vi-polysaccharide of s. Typhi to tetanus toxoid as the carrier protein, responsible for producing improved t-dependent immune response against typhoid fever caused by salmonella typhi.
Bharat Botech International Limited


07/21/16
20160206720 
 Potomac horse fever isolates patent thumbnailnew patent Potomac horse fever isolates
The present invention discloses novel isolates of neorickettsia risticii, compositions comprising such isolates, vaccines and methods for using such vaccines against potomac horse fever.. .
Intervet Inc.


07/21/16
20160206716 
 Compositions comprising angiogenic factors and methods of use thereof patent thumbnailnew patent Compositions comprising angiogenic factors and methods of use thereof
The present invention provides recombinant listeria strains comprising an angiogenic factor, recombinant polypeptides comprising an angiogenic factor operatively linked to a polypeptide comprising a pest-like sequence, recombinant nucleotide molecules encoding same, related vaccines, and immunogenic and therapeutic methods utilizing same.. .
The Trustees Of The University Of Pennsylvania


07/21/16
20160206715 
 Specific multivalent virus-like particle vaccines and uses thereof patent thumbnailnew patent Specific multivalent virus-like particle vaccines and uses thereof
The invention provides a vlp free of a viral genome comprising two or more display polypeptides, nucleic acid molecules, polymers of the nucleic acid, lipopolysaccharides, lipopeptides, peptidoglycans and/or small molecules.. .
The Board Of Trustees Of The Leland Standford Junior University


07/14/16
20160200801 
 Monoclonal antibodies capable of reacting with a plurality of influenza virus a subtypes patent thumbnailMonoclonal antibodies capable of reacting with a plurality of influenza virus a subtypes
Monoclonal antibodies directed against the influenza a virus are described, which have the advantageous and unpredicted property of being able to bind a plurality of subtypes of the influenza a virus. One preferred embodiment is the antibody designated as fab28, which displays a neutralizing activity against a plurality of subtypes of the influenza a virus.
Pomona Ricerca S.r.l.


07/14/16
20160200774 
 Papillomavirus-like particles (vlp) as broad spectrum human papillomavirus (hpv) vaccines patent thumbnailPapillomavirus-like particles (vlp) as broad spectrum human papillomavirus (hpv) vaccines
This invention relates, e.g., to a virus-like particle (vlp) composition assembled from a chimeric polypeptide comprising a papilloma virus (e.g., human papillomavirus, or hpv) l1 major capsid protein, into which is inserted a surface-displayed peptide comprising a neutralizing epitope of a papillomavirus l2 protein. vaccine compositions comprising the vlp are described, as well as methods for inducing an immune response (e.g., vaccinating) a subject against papilloma virus, using the vlp, and kits comprising the vlp, for carrying out a method of the invention..
The Johns Hopkins University


07/14/16
20160200764 

Peptide vaccines for cancers expressing tumor-associated antigens


The present invention provides peptides having an amino acid sequence as set forth in seq id no: 19, 22, 30, 34, 344, 358, 41, 44, 46, 48, 78, 376, 379, 80, 100, 101, 110, 111, 387, 112, 394, 114, 116, 117, 121, 395, 133, 135, 137, 426, 143, 147, 148, 149, 150, 152, 153, 154, 156, 160, 161, 162, 163, 166, 174, 178, 186, 194, 196, 202, 210, 213, 214, 217, 223, 227, 228, 233, 254, 271, 272 or 288, as well as peptides having the above-mentioned amino acid sequences in which 1, 2, or several (e.g., up to 5) amino acids are substituted, deleted, or added, provided the peptides possess cytotoxic t cell inducibility. The present invention also provides drugs for treating or preventing a disease associated with over-expression of the cdh3, epha4, ect2, hig2, inhbb, kif20a, kntc2, ttk and/or urlc10, e.g.
Oncotherapy Science, Inc.


07/14/16
20160200758 

1,2,3-triazole-tethered carbohydrate-di and tri lipidated cysteine conjugates useful as vaccine adjuvants and process for preparation thereof


The present invention also provides process for preparation of carbohydrate-di and tri lipidated cysteine based 1,2,3-triazoles. The carbohydrate-di and tri lipidated cysteine based 1,2,3-triazoles as vaccine adjuvants are useful in formulations for therapeutic and prophylactic vaccines against bacterial, viral, protozoan infections and cancer..

07/14/16
20160199522 

Antibodies and vaccines for use in therapeutic and diagnostic methods for alpha-synuclein-related disorders


Methods for detecting α-synuclein oligomers in vivo comprise administering an antibody to an individual suspected of carrying soluble α-synuclein, wherein the antibody is produced from a stabilized soluble α-synuclein oligomer and is capable of binding the stabilized soluble α-synuclein oligomer, wherein the stabilized soluble α-synuclein oligomer has a lower formation rate to a non-soluble aggregated form than a non-stabilized soluble oligomer of the α-synuclein, and wherein the antibody is labelled with a detectable marker; and detecting the presence of any complex formed between the antibody and soluble α-synuclein by detection of the marker.. .
Bioarctic Neuroscience Ab


07/14/16
20160199504 

Development of novel macromolecule transduction domain with improved cell permeability and using same


The present invention relates to an improved macromolecule transduction domain (mtd), which facilitates permeating the cell membrane of a biologically active molecule, having enhanced cell permeability. Specifically, an improved mtd according to the present invention, compared to an existing mtd, can transmit various types of biologically active molecule from inside the body and inside a test tube more effectively, and thus can be effectively used in a method to genetically alter a biologically active molecule so as to have cell permeability or in a method to transport a biologically active molecule into a cell, or the like.
Procell Therapeutics Inc.


07/14/16
20160199481 

Compositions and methods for directed immunogen evolution and uses thereof


The present disclosure relates to compositions and methods for using a modified virus that infects a cell only if the virus presents a candidate antigen that binds with high affinity to a target antibody, thereby allowing for generation and identification of immunogens useful, for example, as vaccines.. .
Fred Hutchinson Cancer Research Center


07/14/16
20160199478 

Enveloped virus vaccine and production


The present invention provides methods of production of a purified enveloped virus antigen. In particular, it provides purified ross river virus (rrv) antigens, and vaccines comprising purified, inactivated ross river virus (rrv) antigen..
Baxter Healthcare Sa


07/14/16
20160199477 

Attenuated mannheimia haemolytica vaccines and methods of making and use


The present invention provides attenuated m. Haemolitica strains that elicit an immune response in animal against m.
Merial Inc.


07/14/16
20160199473 

Mesothelin vaccines and model systems


Mesothelin can be used as an immunotherapeutic target. It induces a cytolytic t cell response.
The Johns Hopkins University


07/14/16
20160199440 

Designed peptides for tight junction barrier modulation


According to aspects illustrated herein, there is provided an agent that transiently disrupts claudin-1 within tight junctions. The agent includes a peptide having at least 40% polar, uncharged amino acid residues and a self-assembled β-sheet secondary structure.
University Of Rochester


07/07/16
20160194663 

Replication-defective arenavirus vectors


The invention relates to an infectious arenavirus particle that is engineered to contain a genome with the ability to amplify and express its genetic information in infected cells but unable to produce further infectious progeny particles in normal, not genetically engineered cells. One or more of the four arenavirus open reading frames glycoprotein (gp), nucleoprotein (np), matrix protein z and rna-dependent rna polymerase l are removed or mutated to prevent replication in normal cells but still allowing gene expression in arenavirus vector-infected cells, and foreign genes coding for an antigen or other protein of interest or nucleic acids modulating host gene expression are expressed under control of the arenavirus promoters, internal ribosome entry sites or under control of regulatory elements that can be read by the viral rna-dependent rna polymerase, cellular rna polymerase i, rna polymerase ii or rna polymerase iii.
UniversitÄt ZÜrich


07/07/16
20160194662 

Recombinant virus-like particles encoded by multi-gene vector


The invention describes novel virus-like particles for use as vaccines, diagnostic tools and r&d tools based on recombinant dna and cell cultivation techniques for production. The recombinant virus-like particles of the invention are assembled by polypeptide chains that incorporate several, in particular two or more, different epitopes which are selected either (a) from different viral strains of the same virus and/or (b) from different serotypes of the same virus and/or (c) from different viral strains specific for different hosts.
Pfizer Inc.


07/07/16
20160194377 

Crystal structure of staphylococcus aureus clumping factor a in complex with fibrinogen derived peptide and uses thereof


The present invention discloses crystal structure of staphylococcus aureus clumping factor a (clfa) in complex with fibrinogen (fg) derived peptide. Also, the present invention also discloses the use of this structure in the design of clfa targeted vaccines and therapeutic agents (including monoclonal antibodies).
The Texas A&m University System


07/07/16
20160193350 

Phosphorylcholine conjugates and uses thereof


The present invention provides phosphorylcholine (pc)-conjugates and pharmaceutical compositions, particularly vaccines comprising same for the prevention or treatment of autoimmune diseases. In particular, the pc-conjugates of the present invention are effective in preventing or treating autoimmune diseases associated with pathological inflammation..
Tel Hashomer Medical Research Infrastructure And Services Ltd.


07/07/16
20160193330 

Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections


This invention describes novel adjuvant compositions and formulations with excellent stability at refrigerated and room temperatures and up to and about 37° c. That can be produced at remarkably low costs.
Sequoia Sciences, Inc


07/07/16
20160193326 

Vaccine compositions for drug addiction


The present invention relates generally to vaccines for drug addiction. In particular, the present disclosure provides adjuvants for significantly improving immune responses generated against addictive drug haptens..
Immune Design Corp.


07/07/16
20160193321 

Making influenza virus vaccines without using eggs


Currently, the steps performed prior to release of influenza strains to vaccine manufacturers involve passaging influenza virus through eggs. The invention aims to provide procedures useful in manufacturing influenza vaccines, in which the use of eggs is reduced, and preferably is avoided altogether.
Novartis Ag


07/07/16
20160193316 

Inducing cellular immune responses to plasmodium falciparum using peptide and nucleic acid compositions


This invention uses our knowledge of the mechanisms by which antigen is recognized by t cells to identify and prepare plasmodium falciparum epitopes, and to develop epitope-based vaccines directed towards malaria. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of malaria.
Epimmune Inc.


07/07/16
20160193315 

Peptides shared among lethal cancers and therapeutic compositions comprising said peptides


The present invention provides cancer peptides related to rapid replication and shared among different histological cancer types. The peptides are provided in compositions for interfering with replication in cancer, in preventive and therapeutic vaccines, and in diagnostic applications.

07/07/16
20160193310 

Rm2 antigens and use thereof


Described herein are synthetic glycan conjugates, immmunogenic compositions thereof, vaccines thereof, and kits thereof. The present invention further provides methods of using the synthetic glycan conjugates, immunogenic compositions, or vaccines thereof to treat and/or prevent and/or diagnose proliferative diseases such as cancer.
Academia Sinica


06/30/16
20160187351 

Method for the absolute quantification of naturally processed hla-restricted cancer peptides


The present invention relates to a method for the absolute quantification of naturally processed hla-restricted cancer peptides, i.e. The determination of the copy number of peptide(s) as presented per cell.

06/30/16
20160186260 

Cancer vaccination with antigen evolution


The invention provides methods for treating with cancer vaccines patients whose cancers undergo clonal evolution. The invention makes use of a series of cancer vaccines to stimulate a patient's immune system to mount both a humoral and cellular immune response against cancer cells as cancer-specific antigens on the cancer cells change by clonal evolution.

06/30/16
20160186158 

Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis


Compositions and methods for preventing, treating and detecting leishmaniasis are disclosed. The compositions generally comprise polypeptides comprising leishmania antigens as well as polynucleotides encoding such polypeptides..

06/30/16
20160185865 

Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use


The present invention provides affinity matured humanized monoclonal antibodies, bi-specific antibodies, antibody conjugates, and fusion proteins that bind to the chemokine receptor ccr4. This antibody is derived from mab 1567 and recognizes the same epitope.

06/30/16
20160185831 

Nucleic acids for treatment of allergies


The present invention provides dna vaccines for the treatment of allergies. The vaccines comprise the coding sequence for one or more allergenic epitopes, and preferably the full protein sequence, of the allergenic protein from which the epitope(s) is derived, fused inframe with the lumenal domain of the lysosomal associated membrane protein (lamp) and the targeting sequence of lamp.

06/30/16
20160185827 

Vaccines for preventing meningococcal infections


The present invention stems from the finding that the interaction between the β2 adrenoceptor (β2ap) and type iv pilus-associated proteins initiates a process leading to the opening of the blood-brain barrier. The invention therefore pertains to a vaccine for preventing the spreading of meningococci into the meningeal space, wherein said vaccine allows the production of antibodies inhibiting the interaction between the type iv pilus-associated proteins and the β2ap..

06/30/16
20160185826 

Virus-like particle vaccines


The invention is directed to dimeric fusion proteins and virus-like particles comprising such dimeric fusion proteins. These dimeric fusion proteins comprise an antigen or antigenic fragment carried between two viral structural proteins or fragments thereof, with or without linkers, in a manner that, relative to traditional monomeric platforms, minimizes steric hindrance among the antigen or antigenic fragment and the viral structural proteins or fragments thereof.

06/30/16
20160184421 

Immunotherapeutic targets against staphylococcus aureus


The subject invention pertains to vaccine formulations and antibodies, and related methods, for the treatment and/or prevention of s. Aureus infection.

06/23/16
20160176985 

Humanized monoclonal antibodies and methods of use


The present invention comprises a humanized monoclonal antibody that binds to the chemokine receptor ccr4. This antibody is derived from mab 1567 and recognizes the same epitope.

06/23/16
20160176975 

Generation of a cancer-specific immune response toward muc1 and cancer specific muc1 antibodies


The present invention provides a method for inducing a cancer specific immune response against muc1 using an immunogenic glycopeptide. Other aspects of the invention are a pharmaceutical composition comprising the immunogenic glycopeptide and a cancer vaccine comprising the immunogenic glycopeptide.

06/23/16
20160176953 

Human antibodies to influenza hemagglutinin


The present invention provides monoclonal antibodies, or antigen-binding fragments thereof, that bind to the influenza hemagglutinin (ha) protein, pharmaceutical compositions comprising the antibodies and methods of use. The antibodies of the invention are useful for inhibiting or neutralizing influenza virus activity, thus providing a means of treating or preventing influenza infection in humans.

06/23/16
20160175433 

Lipidated immune response modifier compound compositions, formulations, and methods


The compound n-(4-{[4-amino-2-butyl-1h-imidazo[4,5-c]quinolin-1-yl]oxyl}butyl)octadecanamide is a useful drug compound for enhancing immune response and can be used, for example, as a vaccine adjuvant and a cancer treatment.. .

06/23/16
20160175432 

An oil-in-water emulsion containing no surfactant and use thereof


The present invention discloses an oil-in-water emulsion containing no surfactant, which comprises a metabolizable oil phase, an aqueous phase and oil-water amphipathic solid particles dispersed in the aqueous phase and having biocompatibility, wherein the oil phase comprises squalene or/and tocol; the aqueous phase is any one selected from the group consisting of purified water, water for injection, glycerine aqueous solution, buffering salts aqueous solution or clinically usable transfusion, or the combination of at least two selected therefrom; the solid particles have an average particle size in a scale of from nanometer to micrometer. The emulsion of the present invention can be used as vaccine adjuvant, drug delivery carrier or sustained/controlled-release carrier, and have the controllable properties.

06/23/16
20160175430 

Modified polysaccharides for conjugate vaccines


The present invention relates to methods of manufacture of immunogenic glycoconjugates, in particular for use in pharmaceutical compositions for inducing a therapeutic immune response in a subject. The immunogenic glycoconjugates of the invention comprise one or more oligosaccharides or polysaccharides that are conjugated to one or more carrier proteins via an active aldehyde group.

06/23/16
20160175427 

Influenza nucleic acid molecules and vaccines made therefrom


Provided herein are nucleic acid sequences that encode novel consensus amino acid sequences of ha influenza a of serotype h7n9 alone and in combination with ha hemagglutinin and/or influenza b hemagglutinin, as well as genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an immune response against one or more influenza a serotypes and/or influenza b serotypes, or combinations thereof, using the vaccines that are provided..

06/23/16
20160175418 

Ureaplasma vaccine and antibodies


The present invention encompasses methods and compositions for ureaplasma infection prevention and/or treatment. In specific cases, the invention concerns vaccines for ureaplasma, including dna vaccines.

06/23/16
20160175417 

Purified plasmodium and vaccine compositions


Disclosed are substantially purified plasmodium sporozoites and preparations of plasmodium sporozoites substantially separated from attendant non-sporozoite material, where the preparations of plasmodium sporozoites have increasing levels of purity. Vaccines and pharmaceutical compositions comprising purified plasmodium sporozoites are likewise provided.

06/23/16
20160175416 

Allogeneic tumor cell vaccination


The present invention relates to cancer immunotherapy, specifically to allogeneic tumor cell vaccines. According to some embodiments, the invention provides novel cell lines useful as therapeutic cell vaccine compositions.

06/23/16
20160175415 

Methods and compositions using listeria for enhancing immunogenicity by prime boost


Provided herein are prime-boost regimens and materials used therein. The prime-boost regimens enhance the immune response to a target antigen.

06/23/16
20160175413 

Method and composition for treating sarcopenia


A method of treating sarcopenia comprises immunizing a subject in need thereof against age-modified proteins or peptides of a cell. Immunizing a subject includes administering a vaccine that comprises an age antigen.

06/16/16
20160169888 

Proteins expressed by mycobacterium tuberculosis and not by bcg and their use as diagnostic reagents and vaccines


The present invention is directed to reagents useful for generating immune responses to mycobacterium tuberculosis and for diagnosing infection and disease in a subject that has been exposed to m. Tuberculosis..
Rutgers, The State University Of New Jersey


06/16/16
20160166768 

Apparatus and methods for self-administration of vaccines and other medicaments


A medicament delivery device includes a housing, a medicament container disposed within the housing, an activation mechanism, a cover and an electronic circuit system. The activation mechanism includes an energy storage member configured to produce a force to deliver the dose of a medicament and/or vaccine.
Kaleo, Inc.


06/16/16
20160166711 

Rabies vaccine


Furthermore it also discloses the use of the mrna sequence or the composition comprising a plurality of mrna sequences for the preparation of a pharmaceutical composition, especially a vaccine, e.g. For use in the prophylaxis or treatment of rabies virus infections.

06/16/16
20160166697 

Method of treating cancer


The invention provides a method for treating cancer using a coadministration strategy that combines local codelivery of a therapeutic agent and an intracellular penetration enhancing agent, and optionally in further combination with local administration of an immunotherapeutic agent, such as a cancer vaccine or nkt agonist. The invention also provides a method for treating cancer using an intracellular penetration enhancing agent.
Intensity Therapeutics, Inc.


06/16/16
20160166686 

Mini-intronic plasmid dna vaccines in combination with lag3 blockade


It is disclosed herein that (a) an anti-tumor dna vaccine delivered using a mip dna vector is a less effective tumor treatment than the corresponding anti-tumor dna vaccine delivered using a conventional pdna vector, despite the mip dna vector eliciting a higher frequency of antigen-specific cd8+ t cells; and (b) tumor infiltrating cd8+ t cells in animals immunized with the mip dna vector express higher levels of the immune checkpoint protein lag-3 than animals immunized with a conventional pdna vector, while the expression levels of other immune checkpoint proteins was the same for both groups. Based on these findings, improved methods and compositions for administering dna vaccines are disclosed.
Wisconsin Alumni Research Foundation


06/16/16
20160166681 

Toll-like receptor agonists


Compounds described herein can be used for therapeutic purposes. The compounds can be tlr agonists, such as tlr7 or tlr8 agonists.

06/16/16
20160166674 

Vaccines for serogroup x meningococcus


A method for immunising a subject against serogroup x meningococcus by administering a vaccine comprising one, two or all three of: (i) a meningococcal fhbp antigen; (ii) a meningococcal nhba antigen; and/or (iii) a meningococcal nada antigen. The vaccine may also include meningococcal outer membrane vesicles..
Institut Pasteur


06/16/16
20160166673 

Staphylococcus aureus proteins and nucleic acids


The invention provides proteins from staphylococcus aureus including amino acid sequences and the corresponding nucleotide sequences. The proteins are useful for vaccines, immunogenic compositions, diagnostics, enzymatic studies and also as targets for antibiotics..
Glaxosmithkline Biologicals Sa


06/16/16
20160166670 

Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections


This invention describes novel adjuvant compositions and formulations with excellent stability at refrigerated and room temperatures and up to and about 37° c. That can be produced at remarkably low costs.
Sequoia Sciences, Inc


06/16/16
20160166663 

Vaccine formulations that induce a th2 immune response


The present invention relates to compositions and methods for the prevention and treatment of neurodegenerative diseases, such alzheimer's disease, that are caused by misfolding, aggregating proteins. The compositions and methods of the present invention comprise a vaccine formulation comprising an antigen selected from the group consisting of i) amyloid-β or a peptide that has in its amino acid sequence part of the amyloid-β amino acid sequence, ii) hyperphosphorylated tau protein or one of its hyperphoshorylated peptides, or iii) a combination of antigens derived from groups i) and ii) and that are formulated with a non-acylated or deacylated, natural or synthetic, bidesmosidic triterpene glycoside carrying an aldehyde or ketone group, which acts as an adjuvant or immune agonist.
Qantu Therapeutics, Inc.


06/16/16
20160166661 

Antibody-mediated anti-tumor activity induced by reishi mushroom polysaccharides


Immunogenic compositions, cancer vaccines and methods for treating cancer comprising fms, the fucose-enriched polysaccharide fraction from reishi f3, are provided. Compositions comprise fucose-enriched reishi polysaccharide fraction (fms) mw=˜35 kda, wherein the fms is isolated by size-exclusion chromatography from reishi f3, and the fms comprises polysaccharides having primarily a backbone selected from 1,4-mannan and 1,6-α-galactan, wherein the backbone is linked to a terminal fucose-containing side-chain immunogenic compositions comprising glycolipid adjuvants are provided.
Academia Sinica


06/09/16
20160159864 

Complexes of cytomegalovirus proteins


This disclosure provides an isolated human cytomegalovirus (hcmv) membrane protein complex, wherein said complex comprises gh, gl and at least one more hcmv glycoprotein. In some embodiments the complex consists of gh, gl and go.
Novartis Ag


06/09/16
20160158351 

Pharmaceutical compositions comprising attenuated plasmodium sporozoites and glycolipid adjuvants


Disclosed herein are pharmaceutical compositions comprising plasmodium sporozoite-stage parasites and compatible glycolipid adjuvants useful in vaccines for preventing or reducing the risk of malaria. In particular, human host range plasmodium and analogues of α-galactosylceramide (α-galcer), a ligand for natural killer t (nkt) cells, are combined in pharmaceutical compositions, which are useful as vaccines against malaria.
The Rockefeller University


06/09/16
20160158344 

Methods and compositions of protein antigens for the diagnosis and treatment of herpes simplex viruses type 1 and 2


Contemplated compositions, devices, and methods are drawn to various antigens from herpes simplex virus type 1 (hsv-1) and herpes simplex virus type 2 (hsv-2) and their use in vaccines, therapeutic agents, and various diagnostic tests. In particularly preferred aspects, the antigens are immunodominant and have quantified and known relative reactivities with respect to sera of a population infected with the pathogen, and/or have a known association with a disease parameter..
Immport Therapeutics, Inc.


06/09/16
20160158343 

Recombinant herpes simplex virus 2 (hsv-2) vaccine vectors


Recombinant herpes simplex virus 2 (hsv-2) vaccine vectors, virions thereof, compositions and vaccines comprising such, and methods of use thereof are each provided.. .
Albert Einstein College Of Medicine, Inc.


06/09/16
20160158342 

Vaccines for diseases caused by viruses of the family of reoviridae


The invention relates to methods for producing a propagation-competent strain of a mutant reoviridae virus, and to a propagation-competent strain of a mutant reoviridae virus that is obtainable by a method of the invention. The invention further relates to a propagation-competent strain of a mutant reoviridae virus, comprising a deletion of a genetic region that is relevant for propagation of the virus, and to a vaccine, comprising a propagation-competent strain of a mutant reoviridae virus..
Stichting Dienst Landbouwkundig Onderzoek


06/09/16
20160158340 

Influenza vaccines containing hemagglutinin and matrix proteins


An immunological composition comprising influenza virus haemagglutinin and matrix proteins. These may be from influenza viruses grown in call culture rather than eggs.
Seqirus Uk Ltd.


06/09/16
20160158336 

Attenuated mannheimia haemolytica vaccines and methods of making and use


The present invention provides attenuated m. Haemolytica strains that elicit an immune response in animals against m.

06/09/16
20160158331 

Compositions and methods for treatment of non-hodgkins lymphoma


The present invention provides recombinant peptides comprising a b cell receptor (bcr) or a fragment thereof, nucleotide molecules encoding same, and vaccines and vectors comprising same; and methods of treating, inducing an immune response against, inducing a regression of, and suppressing a formation of a lymphoma, comprising administering same. The present invention also provides methods of inducing a humoral immune response in an animal against an antigen, comprising administering to the animal a fusion peptide comprising an llo protein or fragment thereof fused to the antigen..
The Trustees Of The University Of Pennsylvania


06/09/16
20160158329 

Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis


Compositions and methods for preventing, treating and detecting leishmaniasis are disclosed. The compositions generally comprise polypeptides comprising one or more leishmania antigens as well as polynucleotides encoding such polypeptides..
Infectious Disease Research Institute


06/09/16
20160158327 

Genetically modified babesia parasites expressing protective tick antigens and uses thereof


The present invention relates to methods for stable transfection of babesia parasites, and for vaccines conferring immunity against parasitic arthropods.. .
The United States Of America As Represented By The Secretary Of Agriculture


06/02/16
20160153992 

Mutated parvovirus structural proteins as vaccines


The present invention is related to a method for identifying a parvovirus mutated structural protein capable of specifically binding to a binder for an antigen, a parvovirus mutated structural protein which comprises at least one b-cell epitope heterologous to the parvovirus, a multimeric structure comprising the protein, a nucleic acid encoding the protein, a virus or cell comprising the protein, a method of preparing the protein, a medicament comprising the protein, nucleic acid or multimeric structure and its use.. .
Medigene Ag


06/02/16
20160153986 

Proteins expressed by mycobacterium tuberculosis and not by bcg and their use as diagnostic reagents and vaccines


The present invention is directed to reagents useful for generating immune responses to mycobacterium tuberculosis and for diagnosing infection and disease in a subject that has been exposed to m. Tuberculosis..
Rutgers, The State University Of New Jersey


06/02/16
20160152956 

Method for selecting a permissive cell line for replicating avian viruses


The present invention relates to a method for obtaining an untransformed avian cell line enabling in vitro avian virus replication. Said method includes the following steps: a) culturing avian embryonic stem cells in the presence of a stroma for at least 3 days; b) culturing for at least 2 days in a medium having a low serum concentration; c) culturing for at least 2 days in a medium having a low serum concentration containing 1 to 10 mm of hexamethyleme bisacetamide (hmba); d) culturing for at least 10 days in a medium having a low serum concentration; and e) culturing or freezing an avian cell line enabling avian virus replication.
Institut National De La Recherche Agronomique


06/02/16
20160152666 

Recombinant viral vectors


The present relation relates to recombinant vesicular stomatitis virus for use as prophylactic and therapeutic vaccines for infectious diseases of aids. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention..
International Aids Vaccine Initiative


06/02/16
20160151483 

Beta-glycolipids for use as adjuvants


The present invention relates to beta-glycolipid derivatives, their preparation and use as adjuvants in vaccines, as being suitable for being co-administered with antigens for vaccine prophylaxis and therapy. In certain embodiments, the beta-glycol-lipid derivatives of the invention also in their salified or complex form, are suitable for being co-administered with antigens for both therapeutic and prophylactic purposes or for vaccine prophylaxis and therapy..
Consiglio Nazionale Delle Ricerche


06/02/16
20160151482 

Mesoporous alum nanoparticles as a universal platform for antigen adsorption, presentation, and delivery


The present invention relates to mesoporous alum nanoparticles which can be used as a universal platform for antigen adsorption, presentation and delivery to provide immune compositions, including vaccines and to generate an immune response (preferably, both humoral and cell mediated immune response), preferably a heightened immune response to the presentation of one or more antigens to a patient or subject.. .
Sandia Corporation


06/02/16
20160151480 

Universal influenza vaccine


The present invention includes an isolated antigen against influenza a and a method of making the same that includes an ectodomain of influenza a matrix protein 2 (m2e) and a stem region of an influenza a hemagglutinin 2 (ha2) protein and an adjuvant. The invention further includes formulating the antigen into an isolated immune response stimulating fusion protein and/or a vaccine..
Texas Tech University System


06/02/16
20160151474 

Vaccination in elderly patients


The present invention relates to vaccines comprising at least one mrna encoding at least one antigen for use in the treatment of a disease in an elderly patient preferably exhibiting an age of at least 50 years, more preferably of at least 55 years, 60 years, 65 years, 70 years, or older, wherein the treatment comprises vaccination of the patient and eliciting an immune response in said patient. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit..
Curevac Ag


06/02/16
20160151473 

Vaccines using high-dose cytokines


The present invention relates to the field of cancer immunotherapy. In particular, vaccines are administered in conjunction with high doses of cytokines to enhance an anti-tumor immune response..
Sunnybrook And Women's College Health Sciences Center


05/26/16
20160146811 

Ompa and asp14 in vaccine compositions and as diagnostic targets


Anaplasma phagocytophilum surface proteins asp14 and ompa and homologous genes from anaplasmatacaea family members are used in compositions suitable for vaccines to treat or prevent infections caused by tick-born bacteria of the anaplasmatacaea family. Asp14 and/or ompa proteins or peptide fragments may be used in combination with other anaplasmatacaea surface proteins to elicit an immune response.
Virginia Commonwealth University


05/26/16
20160145320 

Broad-spectrum monoclonal antibody recognizing ha1 domain of hemagglutinin of influenza virus


The invention relates to antibodies recognizing epitopes on ha1 domain of hemagglutinin (ha) protein of influenza virus, cell lines for producing the antibodies, and uses thereof. The antibodies according to the invention can specifically bind to ha1 domain of different ha subtypes and specifically bind to ha1 domain of hemagglutinin (ha) protein of h1 subtype (including seasonal h1n1 and 2009 pandemic h1n1) and h5 subtype of influenza viruses.
Xiamen University


05/26/16
20160145255 

Non-nucleoside reverse transcriptase inhibitors


Are hiv reverse transcriptase inhibitors, wherein r1, r2, re, l, m and z are defined herein. The compounds of formula i and their pharmaceutically acceptable salts are useful in the inhibition of hiv reverse transcriptase, the prophylaxis and treatment of infection by hiv and in the prophylaxis, delay in the onset or progression, and treatment of aids.

05/26/16
20160144023 

Dry solid aluminum adjuvant-containing vaccines and related methods thereof


Described herein are dry vaccine compositions and methods of freezing aluminum-containing vaccines such that when converted into a dried powder, the dry vaccine can be readily reconstituted to form a stable liquid vaccine without significant loss of activity.. .
Board Of Regents, The University Of Texas System


05/19/16
20160137987 

Recombinant influenza viruses for vaccines and gene therapy


The invention provides compositions and methods useful to prepare segmented, negative strand rna viruses, e.g., orthomyxoviruses such as influenza a viruses, entirely from cloned cdnas and in the absence of helper virus.. .
Wisconsin Alumni Research Foundation


05/19/16
20160136285 

An isolated immunogenic bacterial antigen and its use in the prevention and treatment of infections caused by gram-negative bacteria


The subject of the present invention is an isolated antigen being an immunogenic form of the common enterobacterial antigen (eca) of gram-negative bacteria of the family enterobacteriaceae: eca combined with lipopolysaccharide (ecalps); a glycoconjugate of inactivated form of this antigen with a protein, as well as compositions and vaccines containing such an antigen/glycoconjugate designed for the prevention and treatment infections caused by gram-negative bacteria.. .
Wroclawskie Centrum Badan Eit+ Sp. Z O.o.


05/19/16
20160136269 

Composition and treating cancer


Pharmaceutical compositions useful as vaccines are described containing a purified surface or excreted protein qualitatively or quantitatively associated with a type of cancer, at least one interleukin (il), and at least one colony stimulating factor (csf), where the purified surface or excreted protein is provided in an amount sufficient to induce an immune response in an individual administered the composition. Such compositions can be used in methods for treating individuals having cancer, and for inducing an immunotherapeutic response in the same..
Oncbiomune, Inc.


05/19/16
20160136266 

Vaccine system for vaccine adjuvant


The present invention provides adjuvant compositions that have improved stability, increased potency and which provide an enhanced th1 response. The present invention also provides methods of making those compositions and administration of the improved adjuvant compositions.
Vaxform Llc


05/19/16
20160136265 

Pharmaceutical composition for viral immunotherapy and uses thereof


The present disclosure relates to a method of overcoming host immune tolerance in a subject having chronic hepatitis b virus (hbv) infection, comprising administering to the subject an immunomodulatory agent and a recombinant hbv vaccine, such that the immune tolerance of the chronic hbv infection in the subject is overcome. Moreover, the present disclosure relates to a method of treating chronic hbv infection in a subject in need thereof, comprising administering to the subject a first anti-viral agent, an immunomodulatory agent and a recombinant hepatitis b vaccine, such that the hbv infection in the subject is treated..
Fudan University


05/19/16
20160136264 

Hepatitis b vaccine


Disclosed is a composition comprising: i) hbsag, a fragment thereof, a variant thereof, or the mixture of at least two of them, ii) hbcag1-x, a fragment thereof, a variant of the antigen or the antigen fragment, or the mixture of at least two of them, wherein x is an integer of from 149 to 183, iii) cpg-odn, 21 bases long, which is a phosphorothioate oligonucleotide and includes two or more copies of 5′-ntcgtt-3′ motifs. The use of the composition in the treatment of hbv-infection and hbv-induced diseases, and the therapy methods of hbv-infection and hbv-induced diseases are also disclosed..
Jiangsu Theravac Bio-pharmaceutical Co., Ltd.


05/19/16
20160136262 

Influenza virus vaccines and uses thereof


Provided are influenza hemagglutinin stem domain polypeptides comprising (a) an influenza hemagglutinin ha1 domain that comprises an ha1 n-terminal stem segment comprising the amino acids from position 1 to position x, preferably from position p to position x, of the ha1 domain, covalently linked by a linking sequence of 0-50 amino acid residues to an ha1 c-terminal stem segment, comprising the amino acids from position y to and including the c-terminal amino acid of the ha1 domain; and (b) an influenza hemagglutinin ha2 domain, wherein the hemagglutinin stem domain polypeptide is resistant to protease cleavage at the junction between ha1 and ha2, and wherein one or more amino acid of the amino acids at positions 337, 340, 352, 353, 402, 406, 409, 413 and/or 416 have been mutated, as compared to the corresponding positions in wild-type influenza ha.. .
Crucell Holland B.v.


05/19/16
20160136261 

Live attenuated vaccines for influenza viruses


The subject invention pertains to attenuated influenza viruses, and related vaccines and methods, comprising a genetically modified viral genome. The genetically modified viral genome comprises a disruption in the non-structural (ns1) coding segment and one or more base substitution in the matrix membrane protein coding segment.
The University Of Hong Kong


05/19/16
20160136260 

Attenuated influenza vaccines and uses thereof


Provided herein are attenuated influenza viruses and methods of making attenuated influenza viruses.. .
University Of Rochester


05/19/16
20160136257 

Protein matrix vaccines and related methods of making and administering such vaccines


The invention relates to vaccine compositions having a carrier protein and an antigen of interest entrapped in a complex, methods of making such vaccines, and methods of vaccine administration.. .
President And Fellows Of Harvard College


05/19/16
20160136256 

Polysaccharide-protein conjugate vaccines


Methods for synthesis and manufacture of polysaccharide-protein conjugate vaccines at high yield are provided. The methods involve reaction of a hydrazide group on one reactant with an aldehyde or cyanate ester group on the other reactant.
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv


05/19/16
20160136255 

Vaccination with recombinant mycobacterium tuberculosis pknd attenuates bacterial dissemination to the brain


Vaccines comprising mycobacterium tuberculosis (m. Tuberculosis) pknd sensor polypeptides, compositions, kits, and methods of use for treating central nervous system tuberculosis are disclosed.
The Johns Hopkins University


05/19/16
20160136253 

Vaccines against pregnancy-associated malaria


The present invention relates to combinations of polypeptides or of polynucleotides corresponding to a specific region of the n-terminal portion of the var2csa protein of different parasitic families or lines of plasmodium falciparum, and to their use in the prevention of pregnancy-associated malaria. The invention also relates to immunogenic compositions and to vaccines useful for preventing malaria in pregnant women..
Institut De Recherche Pour Le DÉvelopment (ird)


05/19/16
20160136250 

Hydrophobic preparations


The present invention relates to preparations of substances in hydrophobic solvents in which they would not normally be soluble and to processes for obtaining these preparations. In particular, the invention relates to preparations of hydrophilic species in hydrophobic solvents such as oils.
Vaxcine Ltd.






Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Vaccine for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Vaccine with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.3185

5193

2 - 1 - 112